Neuroendocrine Tumor Specialized Programs of Research Excellence (SPORE) in Human Cancer

人类癌症神经内分泌肿瘤卓越研究专门计划 (SPORE)

基本信息

批准号：
9756316
负责人：
DAWN E QUELLE
金额：
$ 213.9万
依托单位：
UNIVERSITY OF IOWA
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-09-01 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9756316
关键词：
90Y Adult Advocacy Bioinformatics Biological Markers Biometry Biotechnology Bone Marrow Cancer Patient Child Chronic Clinic Clinical Clinical Research Collaborations Communication Complement Data Analyses Data Quality Databases Development Diagnosis Diagnostic Diagnostic Imaging Diagnostic Procedure Diffuse Disease Early Diagnosis Effectiveness Evidence based treatment Expression Profiling Face G-Protein-Coupled Receptors Genes Genetic Genetic study Genomic approach Human Image Incidence Industry Innovative Therapy Institution Institutional Review Boards Insurance Investments Iowa Islet Cell Tumor Kidney Length Malignant Neoplasms Molecular Mutate Neuroendocrine Therapy Neuroendocrine Tumors Neurosecretory Systems Pathway interactions Patients Pharmacologic Substance Physicians Positron-Emission Tomography Prevalence Privatization Prognostic Marker Quality Control Quality of life Radiation Dose Unit Radioisotopes Radiopharmaceuticals Recommendation Registries Research Research Support Resistance Small Intestines Source Specialized Program of Research Excellence Structure Support Groups Toxic effect Tracer Translating Translational Research Tumor Bank Tumor Tissue United States Universities accurate diagnosis career development chemotherapeutic agent exome imaging agent improved innovation metaiodobenzylguanidine molecular marker multidisciplinary new therapeutic target novel diagnostics novel strategies novel therapeutics outreach patient population public health relevance rare cancer theranostics therapeutic target translational research program translational scientist tumor

项目摘要

DESCRIPTION (provided by applicant): Rare tumors present several challenges, including lack of evidence based treatment recommendations, unwillingness of insurance companies to support unproven therapies, and keen competition for translational research support that may benefit only a small proportion of all cancer patients. Neuroendocrine tumors (NETs) targeted in this proposal are rare tumors that face all of these challenges. NETs arise from the diffuse neuroendocrine system, occur in both adults and children, and are increasing in both incidence and prevalence in the United States. The University of Iowa is one of only a handful of academic or private institutions in the US where patients with NETs are diagnosed, treated, and regularly followed in a comprehensive manner. A multi-disciplinary NET clinic, an IRB approved registry and database, and a growing translational research program are housed at the University of Iowa. We have collaborated with pharmaceutical and biotech companies, patient support groups, and other research institutions whose expertise complements our clinical and translational expertise, to build a neuroendocrine tumor Center of Excellence. Iowa is poised to house the first SPORE in neuroendocrine tumors where academic, industry, and philanthropic organizations will partner with NCI to increase the length and quality of life for these unique patients. Our Overall Specific Aims are: 1. Support innovative translational research in Neuroendocrine Tumors. 2. Provide support to translational investigators through interactive cores. 3. Enlist and encourage new translational researchers in neuroendocrine tumors through developmental projects and career development. 4. Promote early and accurate diagnosis through outreach to physicians and advocacy groups.

描述（由申请人提供）：罕见肿瘤带来了一些挑战，包括缺乏基于证据的治疗建议、保险公司不愿意支持未经证实的疗法，以及对可能只使一小部分癌症患者受益的转化研究支持的激烈竞争。该提案针对的神经内分泌肿瘤（NET）是面临所有这些挑战的罕见肿瘤。 NET 起源于弥漫性神经内分泌系统，成人和儿童均可发生，并且在美国发病率和患病率均呈上升趋势。爱荷华大学是美国为数不多的对 NET 患者进行全面诊断、治疗和定期随访的学术或私立机构之一。爱荷华大学设有多学科 NET 诊所、IRB 批准的登记处和数据库以及不断发展的转化研究项目。我们与制药和生物技术公司、患者支持团体以及其他研究机构合作，其专业知识与我们的临床和转化专业知识相补充，建立了神经内分泌肿瘤卓越中心。爱荷华州准备在神经内分泌肿瘤中安置第一个 SPORE，学术、工业和慈善组织将与 NCI 合作，以延长这些独特患者的生活长度和质量。我们的总体具体目标是： 1. 支持神经内分泌肿瘤的创新转化研究。 2. 通过互动核心为转化研究者提供支持。 3. 通过发展项目和职业发展招募并鼓励神经内分泌肿瘤领域的新转化研究人员。 4. 通过与医生和倡导团体进行外展活动，促进早期、准确的诊断。